AEON Biopharma Files 2024 Proxy Statement
Ticker: AEON · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1837607
Sentiment: neutral
Topics: proxy-statement, corporate-governance, annual-filing
TL;DR
AEON Biopharma filed its 2024 proxy statement, shareholders vote soon.
AI Summary
AEON Biopharma, Inc. filed its definitive proxy statement for the fiscal year ending December 31, 2024. The filing, dated April 29, 2025, outlines the company's corporate governance and matters to be voted on by shareholders. AEON Biopharma, previously known as Priveterra Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, executive compensation, and voting matters, enabling informed participation in corporate decisions.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material events or financial performance data.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- 2024-12-31 (date) — Fiscal year end
- 20250429 (date) — Filing date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the annual meeting, including details on corporate governance, executive compensation, and matters to be voted upon, as required by Section 14(a) of the Securities Exchange Act of 1934.
What is AEON Biopharma, Inc.'s fiscal year end?
AEON Biopharma, Inc.'s fiscal year ends on December 31.
When was this definitive proxy statement filed?
This definitive proxy statement was filed on April 29, 2025.
What was AEON Biopharma, Inc.'s former company name?
AEON Biopharma, Inc.'s former company name was Priveterra Acquisition Corp.
In which state is AEON Biopharma, Inc. incorporated?
AEON Biopharma, Inc. is incorporated in Delaware (DE).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding AEON Biopharma, Inc. (AEON).